TY - CHAP M1 - Book, Section TI - Chapter 25. Pathology Post-Neoadjuvant Therapy A1 - Symmans, W. Fraser A2 - Kuerer, Henry M. PY - 2010 T2 - Kuerer's Breast Surgical Oncology AB - A central tenet of neoadjuvant clinical trials is that tumor response, as a surrogate end point, should be strongly correlated with long-term patient survival.1,2 Otherwise, the value of neoadjuvant treatment would be to convert a tumor to operability or to increase the probability of conservative surgery. However, a close association between pathologic response to treatment and subsequent survival establishes neoadjuvant treatment as a method for clinical trials including operable disease to evaluate promising treatments more purely in terms of direct tumoricidal activity and without confounding variables of natural history and subsequent treatments. Indeed, pathologic complete response (pCR) has been adopted as the primary end point for neoadjuvant trials because it has consistently been associated with long-term survival in neoadjuvant trials using different chemotherapy regimens of variable treatment duration.3-12 If pCR is achieved using current therapies, one can anticipate more than 90% probability of disease-free survival within the first decade of follow-up. SN - PB - The McGraw-Hill Companies CY - New York, NY Y2 - 2024/03/29 UR - accesssurgery.mhmedical.com/content.aspx?aid=6410078 ER -